Article Text

Download PDFPDF
1342 Longitudinal detection of circulating tumour cells in serous and non-serous epithelial ovarian carcinomas
  1. Faye Lewis1,2,3,4,
  2. Mark Ward1,2,3,4,
  3. Catherine O’Gorman2,3,4,
  4. Brian Henderson1,2,3,4,
  5. Sinead Hurley1,2,3,4,
  6. James Beirne3,
  7. Lorraine O’Driscoll2,5,
  8. Ciara Mcnevin2,3,
  9. Tanya Kelly1,2,3,4,
  10. Kathy Gately2,3,6,
  11. Ezgi Oner2,3,6,
  12. Volga Saini2,3,6,
  13. Lucy Norris3,4,
  14. Marika Kanjuga1,2,3,4,
  15. Cara Martin1,2,3,
  16. Patrick Maguire2,3,
  17. Karen Cadoo2,3,
  18. Gavin Mcmanus7,
  19. John J O’Leary1,2,3 and
  20. Sharon A O’Toole1,2,3,4
  1. 1Trinity College Dublin, Histopathology and Morbid Anatomy, Dublin, Ireland
  2. 2St. James’s Hospital, Trinity St. James’s Cancer Institute, Dublin, Ireland
  3. 3Trinity College Dublin, School of Medicine, Dublin, Ireland
  4. 4Trinity College Dublin, Obstetrics and Gynaecology, Dublin, Ireland
  5. 5Trinity College Dublin, School of Pharmacy and Pharmaceutical Sciences, Dublin, Ireland
  6. 6Trinity College Dublin, Clinical Medicine, Dublin, Ireland
  7. 7Trinity College Dublin, School of Biochemistry and Immunology, Dublin, Ireland


Introduction/Background Metastasis is the primary cause of cancer mortality. The migration of tumour cells known as circulating tumour cells (CTCs) in the bloodstream form part of the ‘liquid biopsy’. CTC enumeration serves as prognostic marker in breast, prostate, and colorectal cancers. However, due to technical challenges, its relevance in epithelial ovarian carcinomas (EOC) remains limited. Therefore, we examined CTCs longitudinally in serous and non-serous EOCs.

Methodology Peripheral blood samples were collected from 62 patients with EOC at diagnosis (serous: n=48 (47 high-grade,1 low-grade); non-serous: n=14 (6 clear-cell, 4 endometroid, 1 mucinous, 3 mixed)). A subset underwent primary-cytoreductive surgery (PCRS) with samples collected 2-days post-op (12/32) and from the ovarian vein (19/32). Samples were taken post-chemo for patients receiving neoadjuvant chemotherapy (NACT) (17/30), and at 1-year follow-up or recurrence (22/62). CTCs were enriched using Parsortix® Technology and enumerated [DAPI, CK7, panCK, EpCAM+, CD45-]. CTC counts were correlated with clinicopathological data.

Results CTCs were detected in 56% of patients with EOC at diagnosis (1- 22 CTCs/7.5 mL blood). Those who underwent ovarian vein sampling, 58% had detectable CTCs in the vein sample. Peripheral CTC-positivity rate was 50% 2 days post-PCRS and 41% post-NACT. 62% of samples at 1-year follow-up had CTCs, where 85% of these had recurred. 77% of patients who recurred had CTCs at diagnosis. CTC-positivity had no significant effect on PFS, where median follow-up time was 18 months. No significant differences in CTC counts were observed between serous and non-serous cohorts for sample timepoint, ovarian vein sampling, CA-125 levels (p=0.07), or primary tumour size (p=0.06). CTCs were detected at all sample timepoints in both serous and non-serous EOC.

Conclusion CTCs were detected at all timepoints assessed during treatment of EOC. Enumerating CTCs throughout treatment in EOC is imperative to assess their clinical significance. Ongoing follow-up and longitudinal sampling of this patient cohort continues.

Disclosures None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.